HC Wainwright reissued their buy rating on shares of Abeona Therapeutics (NASDAQ:ABEO - Free Report) in a research report sent to investors on Monday,Benzinga reports. The brokerage currently has a $15.00 price target on the biopharmaceutical company's stock.
A number of other brokerages have also weighed in on ABEO. StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Wednesday, November 20th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $18.00 price target on shares of Abeona Therapeutics in a research note on Tuesday, October 29th.
View Our Latest Stock Analysis on Abeona Therapeutics
Abeona Therapeutics Stock Performance
Shares of NASDAQ:ABEO traded down $0.03 during trading on Monday, hitting $5.95. 175,522 shares of the company were exchanged, compared to its average volume of 430,314. The company has a debt-to-equity ratio of 0.31, a current ratio of 6.12 and a quick ratio of 6.12. Abeona Therapeutics has a 52-week low of $3.05 and a 52-week high of $9.01. The company has a market cap of $258.65 million, a PE ratio of -2.22 and a beta of 1.52. The stock has a 50 day moving average of $6.20 and a 200 day moving average of $5.29.
Institutional Inflows and Outflows
Hedge funds and other institutional investors have recently bought and sold shares of the business. Acadian Asset Management LLC acquired a new stake in shares of Abeona Therapeutics in the first quarter valued at about $91,000. Western Standard LLC lifted its position in shares of Abeona Therapeutics by 68.5% during the first quarter. Western Standard LLC now owns 1,361,489 shares of the biopharmaceutical company's stock worth $9,871,000 after purchasing an additional 553,377 shares in the last quarter. Rosalind Advisors Inc. bought a new stake in shares of Abeona Therapeutics in the second quarter worth $7,420,000. Bank of New York Mellon Corp grew its position in shares of Abeona Therapeutics by 2.0% during the second quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock worth $515,000 after acquiring an additional 2,434 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Abeona Therapeutics by 581.6% in the second quarter. Renaissance Technologies LLC now owns 503,293 shares of the biopharmaceutical company's stock worth $2,134,000 after purchasing an additional 429,456 shares during the period. 80.56% of the stock is owned by hedge funds and other institutional investors.
About Abeona Therapeutics
(
Get Free Report)
Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.
Further Reading
Before you consider Abeona Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Abeona Therapeutics wasn't on the list.
While Abeona Therapeutics currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Click the link below to learn more about using beta to protect yourself.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
